Efavirenz

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Achtung

• Gefahrenhinweise

  H302：Gesundheitsschädlich bei Verschlucken.

  H360：Kann die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen.

  H410：Sehr giftig für Wasserorganismen mit langfristiger Wirkung.

• Sicherheit

  P202：Vor Gebrauch alle Sicherheitshinweise lesen und verstehen.

  P264：Nach Gebrauch gründlich waschen.

  P264：Nach Gebrauch gründlich waschen.

  P270：Bei Gebrauch nicht essen, trinken oder rauchen.

  P273：Freisetzung in die Umwelt vermeiden.

  P301+P312：BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.

  P308+P313：BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen.

Efavirenz Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  Efavirenz D5 was launched as Sustiva in the US for the treatment of infection by HIV, the virus causing AIDS, in combination with other anti-retroviral agents.
  Efavirenz D5 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) belonging to the 3,1-benzoxazin-2-one chemical class. It is the third non-nucleoside reverse transcriptase inhibitor to have been launched to date, after Nevirapine (1996) and Delavirdine (1997), increasing the arsenal of anti-HIV drugs for treating infected patients in dual or triple combination with nucleoside or other non-nucleoside RTIs, or protease inhibitors.
  Efavirenz D5 can be obtained by two related ways of six steps from 4-chloroaniline ; one of them is based on asymmetric synthesis by enantioselective addition of an acetylide to a trifluoroacetophenone. The anti-HIV activity of Efavirenz D5 was demonstrated against most wild-type and clinical strains of HIV-1, including those with the most frequently observed mutations. Efavirenz D5 has a better pharmacokinetic profile when compared with the preceding drugs of this class ; in particular, in a long-term experiment conducted in cynomolgus monkeys, Efavirenz D5 was shown to easily cross the blood brain barrier leading to an increase of the antiviral concentration in cerebrospinal fluid.

• Chemische Eigenschaften

  White to Slightly Pink Crystalline Powder

• Originator

  Merck & Co. (US)

• Verwenden

  For use in combination treatment of HIV infection (AIDS)

• Verwenden

  antiviral;reverse transcriptase inhibitor

• Verwenden

  Efavirenz D5 is a nonnucleoside HIV-1 reverse transcriptase inhibitor. Antiviral

• Indications

  Efavirenz (Sustiva) is approved for the therapy of HIV infection of adults and children and is also used for postexposure prophylaxis. It is the only NNRTI approved for once-daily dosing. Rash, although rarely severe, is a common adverse effect of efavirenz. Elevated liver enzymes and serum cholesterol also may occur. Central nervous system (CNS) effects in approximately half of patients may include dizziness, headache, insomnia, drowsiness, euphoria, agitation, impaired cognition, nightmares, vivid dreams, and hallucinations. These effects often subside after several weeks to months of therapy.

• Definition

  ChEBI: 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor wit activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.

• Manufacturing Process

  (-)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1- benzoxazin-2-one and (+) 6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl- 1,4-dihydro-2H-3,1-benzoxazin-2-one
  The above products can be produced in the next steps:
  Step A: 2-(2-Amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluoro-3-butyn-2- ol.
  A solution, was prepared from 23 g of cyclopropylacetylene (0.348 mol) in 250 mL of THF by dropwise addition of 116 mL of a 3.0 M solution of ethylmagnesium bromide in ether (0.348 mol) over 1 h. This solution was maintained at 0°C for 1 h, then at 40°C for 3 h. To this solution, recooled to 0°C, 15.56 g of 1-(2-amino-5-chlorophenyl)-2,2,2-trifluoromethylethanone (0.0696 mol), was added as a solid, portionwise over 5 min. The reaction mixture was allowed to stir at 0°C for 1.5 hours. The reaction was quenched at 0°C by dropwise addition of 700 mL of saturated aqueous ammonium chloride solution. The mixture was extracted with 2 times 400 mL portions of ethyl acetate, the combined organic phases were washed with brine and dried over MgSO4. Removal of the drying agent and solvents left a yellow solid. This material was recrystallized from boiling hexanes (100 mL final volume) to afford 14.67 g of 2-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluoro-3- butyn-2-ol. A second crop (2.1 g) was obtained from concentrating the mother liquors. M.p.: 153°-154°C.
  Step B: ()-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H- 3,1-benzoxazin-2-one.
  A solution of 2-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluoro-3- butyn-2-ol (15.00 g, 0.0518 mol) and 41.98 g (0.259 mol) of 1,1'- carbonyldiimidazole in 250 mL of dry THF was stirred under argon at 55°C for 24 hours. The solvent was removed on a rotary evaporator and the residue was partitioned between 500 mL of ethyl acetate and 400 mL of water. The layers were separated and the aqueous phase was extracted once more with ethyl acetate. The combined ethyl acetate extracts were washed with 2 times 200 mL of 2% aqueous HCl, saturated aqueous NaHCO3, and brine. Drying over MgSO4, filtration, and removal of the solvent in vacuo provided 16.42 g of the title compound as a solid. Recrystallization from ethyl acetate/hexane afforded 12.97 g of analytically pure ()-6-chloro-4-cyclopropylethynyl-4- trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one as a white crystals. Melting point: 178°-180°C.
  Step C: 6-Chloro-1-(1S)-camphanoyl-4-cyclopropylethynyl-4-trifluoromethyl- 1,4-dihydro-2H-3,1-benzoxazin-2-one.
  To a solution containing (+)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl- 1,4-dihydro-2H-3,1-benzoxazin-2-one (12.97 g, 0.041 mol), 4- dimethylaminopyridine (1.02 g, 0.0083 mol), and (-)-camphanic acid chloride (14.22 g, 0.06556 mol) in 350 mL of dry dichloromethane, stirred under argon in an ice bath, was added triethylamine (22.84 mL, 0.164 mol). The cooling bath was removed and the reaction was allowed to proceed at room temperature. After 75 min. the reaction was judged complete by thin layer chromatography (SiO2, 4% EtOAc in CHCl3), and the solution was diluted with 500 mL of CHCl3 then washed with 10% citric acid (2X), water (1X), and brine (1X). Drying (MgSO4), filtration, and removal of the solvent in vacuo left a colorless foam. This material was triturated with 200 mL of boiling hexane. On cooling to room temperature the desired diastereomeric camphanate imide precipitated. The solid was collected on a frit, washed with a little cold hexanes and dried in vacuo to give 7.79 g of 6-chloro-1-(1S)-camphanoyl-4- cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one as white crystals. Melting point: 164°-165°C. HPLC purity: 99.2% γ 254 nm.
  Step D: (-)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H- 3,1-benzoxazin-2-one.
  6-Chloro-1-(1S)-camphanoyl-4-cyclopropylethynyl-4-trifluoromethyl-1,2- dihydro-4(H)-3,1-benzoxazin-2-one(7.50 g, 0.01512 mol) was dissolved in 150 mL of n-butanol at 60°C und

• Trademarks

  Sustiva (Bristol-Myers Squibb).

• Therapeutic Function

  Antiviral

• Acquired resistance

  One or more single-codon substitutions in the HIV reverse transcriptase genome at positions 100, 103, 106, 108, 181, 188, 190 and 225 confer reduced susceptibility. Many, but not all, of these point mutations confer reduced susceptibility to other non-nucleoside reverse transcriptase inhibitors.

• Allgemeine Beschreibung

  Efavirenz D5 (Sustiva)84 is also mandated for use with at leasttwo other antiretroviral agents. The compound is morethan 99% protein bound, and CSF concentrations exceedthe free fraction in the serum. Metabolism occurs in theliver. The half-life of a single dose of Efavirenz D5 is 52 to 76hours, and 40 to 55 after multiple doses (the drug inducesits own metabolism). Peak concentration is achieved in 3to 8 hours. Elimination is 14% to 34% in urine (as metabolites)and 16% to 41% in feces (primarily as Efavirenz D5).The oral dosage form is supplied as a capsule.

• Pharmazeutische Anwendungen

  Efavirenz D5 is a synthetic heterocyclic compound formulated for oral administration.

• Biochem/physiol Actions

  Efavirenz is a nonnucleoside reverse transcriptase inhibitor (NNRTI). It is an anti-HIV drug, commonly used in combination therapy for AIDs treatment. It is part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

• Pharmakologie

  Efavirenz interacts with many drugs via the cytochrome P450 pathways. It induces and is metabolized by CYP3A4 and inhibits CYP2C9 and CYP2C19. It should not be given with cisapride, ergot alkaloids, midazolam, or triazolam because of the potential for lifethreatening reactions. Efavirenz has the potential to decrease blood levels of methadone, rifabutin, ketoconazole, and itraconazole. It may inhibit the metabolism of drugs such as alosetron, diazepam, ethinyl estradiol, imipramine, losartan, omeprazole, warfarin, tolbutamide, and topiramate. Efavirenz interacts with cytochrome P450 inducers and substrates (e.g., phenytoin, phenobarbital) in a complex manner; blood levels and side effects should be closely monitored. Patients taking efavirenz should avoid herbal preparations containing St. John’s wort because the herb induces CYP3A4 and may cause drug failure or viral resistance. Saquinavir should not be used as the sole protease inhibitor in a regimen containing efavirenz.

• Pharmakokinetik

  Oral absorption: Not known/available
  C_max 600 mg oral once daily: c. 4.07 mg/L
  C_min 600 mg oral once daily: c. 1.77 mg/L
  Plasma half-life: c. 45 h
  Volume of distribution: c. 2.4 L/kg
  Plasma protein binding: >99%
  Absorption and distribution
  Bioavailability following a standard high-fat meal was increased by an average of 50%, but was unaffected by a standard meal. Distribution into body tissues and fluids has not been fully characterized. It penetrates moderately well into the CNS. The semen:plasma ratio is 0.09 (0.03–0.43). The mean concentration in breast milk is 3.51 mg/L; significant linear correlations have been found between maternal plasma and breast milk.
  Metabolism and excretion
  It is metabolized by cytochrome P₄₅₀ systems to hydroxylated intermediates and excreted after subsequent glucuronidation. Metabolites are not active against HIV.
  It is excreted principally in the feces, both as metabolites and unchanged drug. Up to 34% is recovered in the urine, <1% as unchanged drug. Given this, the impact of renal impairment on efavirenz is likely to be minimal. Caution is recommended in patients with mild–moderate liver disease; it is contraindicated in patients with severe hepatic impairment.
  Dose adjustment is unnecessary when it is co-administered with HIV protease inhibitors or rifampicin (rifampin).

• Clinical Use

  Treatment of HIV-1 infection in adults and children (in combination with other antiretroviral drugs)

• Nebenwirkungen

  The most common (>5%, moderate–severe) adverse effects associated with Efavirenz D5 therapy are rash, dizziness, nausea, headache, fatigue, insomnia and vomiting. Rash occurs in up to 26% of patients, mostly in the first 2 weeks of therapy. It usually resolves within 1 month, but is sufficiently severe to limit treatment in a few cases.
  Dizziness, insomnia, somnolence, impaired concentration, abnormal dreaming and other CNS disturbances have been reported in around 52% of clinical trial participants, with events of moderate to severe intensity occurring in about 3% of patients. Rare (0.2% of patients) episodes of severe delusional or inappropriate behavior and severe acute depression have also been reported. The symptoms commonly begin in the first 2 weeks of treatment but often resolve or substantially improve within a month.
  Elevations in serum hepatic transaminase to levels more than five times the upper limit of normal are observed in about 3% of patients and 8% of those co-infected with viral hepatitis B or C.

• Arzneimittelwechselwirkung

  Potentially hazardous interactions with other drugs
  Antibacterials: concentration of rifabutin reduced.
  Anticoagulants: possibly affects concentration of coumarins.
  Antidepressants: concentration reduced by St John’s wort - avoid.
  Antifungals: itraconazole, posaconazole and voriconazole concentration reduced; voriconazole increases efavirenz concentration - reduce dose of efavirenz by 50% and increase dose of voriconazole to 400 mg twice daily; possibly reduces caspofungin concentration - may possibly need to increase caspofungin dose.
  Antimalarials: concentration of artemether with lumefantrine reduced.
  Antipsychotics: possibly increased risk of ventricular arrhythmias with pimozide - avoid; possibly reduces aripiprazole concentration - increase aripiprazole dose
  Antivirals: concentration of atazanavir and boceprevir reduced - avoid; saquinavir concentration significantly reduced; concentration of daclatasvir, darunavir, dolutegravir, indinavir, lopinavir, telaprevir and possibly etravirine and maraviroc reduced - adjust daclatasvir, darunavir, dolutegravir, lopinavir, maraviroc and telaprevir dose, avoid with etravirine; concentration reduced by nevirapine; monitor LFTs when used in combination with ritonavir.
  Anxiolytics and hypnotics: risk of prolonged sedation with midazolam - avoid.
  Atovaquone: concentration of atovaquone reduced - avoid.
  Ciclosporin: concentration of ciclosporin possibly reduced.
  Cytotoxics: concentration of bosutinib possibly reduced - avoid
  Ergot alkaloids: risk of ergotism - avoid.
  Grapefruit juice: concentration possiblyincreased.
  Guanfacine: concentration of guanfacine possibly reduced, increase dose of guanfacine
  Oestrogens and progestogens: possibly reduced contraceptive effect.
  Orlistat: absorption possibly reduced by orlistat.
  Tacrolimus: possibly affects tacrolimus concentration.
  Ulipristal: possibly reduced contraceptive effect.

• Stoffwechsel

  Studies in humans and in vitro studies using human liver microsomes have demonstrated that efavirenz is principally metabolised by the cytochrome P450 system to hydroxylated metabolites with subsequent glucuronidation of these hydroxylated metabolites. These metabolites are essentially inactive against HIV-1. The in vitro studies suggest that CYP3A4 and CYP2B6 are the major isozymes responsible for efavirenz metabolism and that it inhibited P450 isozymes 2C9, 2C19, and 3A4. In in vitro studies efavirenz did not inhibit CYP2E1 and inhibited CYP2D6 and CYP1A2 only at concentrations well above those achieved clinically
  Approximately 14-34% of a radiolabelled dose of efavirenz was recovered in the urine.

• Einzelnachweise

  [1] young s d, britcher s f, tran l o, et al. l-743, 726 (dmp-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. antimicrobial agents and chemotherapy, 1995, 39(12): 2602-2605.
  [2] de béthune m p. non-nucleoside reverse transcriptase inhibitors (nnrtis), their discovery, development, and use in the treatment of hiv-1 infection: a review of the last 20 years (1989–2009). antiviral research, 2010, 85(1): 75-90.

Efavirenz Upstream-Materialien And Downstream Produkte

Efavirenz Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(527)Suppliers

154598-52-4, Efavirenz Verwandte Suche: